Investigational drug · Phase 2
SRX246
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Aggressive Behavior in Fragile X Syndome.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
7
Any phase or sponsor naming "SRX246"
First trial start
2026
Dec 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SRX246", any sponsor or status.
Conditions studied
As listed on its trial records.
- Aggressive Behavior in Fragile X Syndome
Largest trials
Live from ClinicalTrials.gov: studies naming "SRX246" as an intervention, largest first.
- Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's DiseasePivotal-lookingCompleted
Azevan PharmaceuticalsIndustry
NCT02507284 · 106 participants · Start May 10, 2016 · Primary completion Sep 10, 2018
Drug: SRX246; Placebo · For: Irritable Mood; Huntington's Disease
Sites: Birmingham, Alabama; Los Angeles, California; Sacramento, California · 22 sites in all
Azevan PharmaceuticalsIndustry
NCT02055638 · 97 participants · Start May 2014 · Primary completion May 2016
Drug: SRX246; Placebo · For: Intermittent Explosive Disorder
Sites: Atlanta, Georgia; Chicago, Illinois; O'Fallon, Missouri · 7 sites in all
Azevan PharmaceuticalsIndustry
NCT07328529 · 80 participants (planned) · Start Dec 2026 · Primary completion Dec 2027
Drug: SRX246; Placebo · For: Aggressive Behavior in Fragile X Syndome
Sites: Sacramento, California; Chicago, Illinois; Cincinnati, Ohio
Azevan PharmaceuticalsIndustry
NCT00910455 · 49 participants · Start May 2009 · Primary completion Sep 2009
Drug: SRX246; Placebo · For: Healthy
Sites: Hackensack, New Jersey
Azevan PharmaceuticalsIndustry
NCT02922166 · 36 participants · Start Feb 3, 2017 · Primary completion May 10, 2019
Drug: SRX246; Placebo · For: Fear; Anxiety
Sites: Bethesda, Maryland
Azevan PharmaceuticalsIndustry
NCT02733614 · 33 participants · Start Dec 2016 · Primary completion Oct 2020
Drug: SRX246; Placebo · For: PTSD
Sites: New York, New York
Azevan PharmaceuticalsIndustry
NCT01088932 · 24 participants · Start Mar 2010 · Primary completion Jun 2010
Drug: SRX246 · For: Healthy
Sites: Baltimore, Maryland
Newest research
PubMed records naming it or its code names, newest first.
- Molecular basis of antagonism of the dimeric human arginine vasopressin receptor 1A.
Zhong P, Chu B, Yu Z, et al. · Nat Commun 2026
- The utility of the irritability scale in Huntington's disease patients with evidence of irritability or aggression.
En-Hua Wang J, Simon NG, Brownstein MJ, et al. · Parkinsonism Relat Disord 2024
- A Neuroanatomic and Pathophysiologic Framework for Novel Pharmacological Approaches to the Treatment of Post-traumatic Stress Disorder.
Norred MA, Zuschlag ZD, Hamner MB · Drugs 2024
- A proof-of-concept randomized crossover clinical trial of a first-in-class vasopressin 1a receptor antagonist for PTSD: Design, methods, and recruitment.
Difede J, McAleavey AA, Emrich M, et al. · Contemp Clin Trials Commun 2023
- The Vasopressin 1a Receptor Antagonist SRX246 Reduces Aggressive Behavior in Huntington's Disease.
Maibach HT, Brownstein MJ, Hersch SM, et al. · J Pers Med 2022
- The novel vasopressin receptor (V1aR) antagonist SRX246 reduces anxiety in an experimental model in humans: a randomized proof-of-concept study.
Lago TR, Brownstein MJ, Page E, et al. · Psychopharmacology (Berl) 2021
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.